Liver
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.
Biomea’s Early-Stage Diabetes Drug Placed on Full Clinical Hold, Stock Plummets
Biomea, diabetes, clinical hold, FDA, BMF-219, liver toxicity, stock crash
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.
Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases
Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024